MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis
MRM Health NV, a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics, today reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis (UC).
MRM Health’s MH002-UC-201 study was a multi-center, double-blind, randomized, placebo-controlled trial in 45 UC patients at multiple clinical sites in Belgium, Poland and Czech Republic. The study was designed to evaluate safety (primary endpoint), initial efficacy and mechanistic effects of MH002 over eight weeks, with a further eight-week extension period. More information about the trial is available at clinicaltrialsregister.eu.
The primary endpoint was met with an excellent safety profile and tolerance at a fixed dose of 400mg per day over 16 weeks administration. Treatment-Emergent Adverse Events (TEAE) were reported in 35% of patients allocated to MH002 treatment compared to 57% when treated with placebo and there was no evidence of adverse reactions related to MH002.
Initial efficacy on disease activity was evidenced in clinically relevant parameters, including a 12% improvement in Mayo Endoscopic Severity (MES) score (p=0.05, 1-sided Wilcoxon rank sum test), while placebo worsened by 5%. Stool consistency significantly improved in the MH002 treatment group as from week 2 (p=0.006; 1-sided Student t-test). At the end of the eight-week period, 18% of subjects achieved clinical remission compared to 0% of the placebo group (Per-protocol analysis). As opposed to previous trials with other live biotherapeutics in UC, this study was performed successfully without vancomycin preconditioning.
At a mechanistic level, anti-inflammatory effect was demonstrated with 42% decrease in median fecal calprotectin (a clinically relevant bowel inflammation marker) compared to 18% in placebo at week 8.
“These early results indicate that MH002 is safe and well tolerated by patients, and has potential efficacy in mild-to-moderate UC patients who have not responded sufficiently to first-line treatment,” commented Séverine Vermeire, coordinating investigator of study MH002-UC-201 and Professor of Medicine at the KU Leuven, Belgium. “There is a significant absence of treatments for UC patients, particularly in this population, so I look forward to conducting the full analysis of the data and following MH002’s progression through the clinic.”
Bruce Sands, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York and paid consultant to MRM Health, added: “MH002’s mechanism of action and anti-inflammatory effect in UC look very promising, with the potential of a highly favorable benefit/risk balance, pending larger confirmatory studies. These topline results also suggest that this formulation could have applications across a wider range of other inflammatory bowel disorders, including pouchitis, in which MH002 is also being tested.”
Full analysis and presentation of the data is expected by the end of 2023. The Company has initiated to progress the program into Phase 2/3 development.
Ludo Haazen, Chief Medical Officer at MRM Health, added: “This first clinical study enables us to move forward with our clinical programme in UC. We are excited to see that MH002 differentiated in this early study significantly and consistently from placebo in clinically relevant parameters, including the centrally assessed MES, which was supported by the mechanistic parameters we have measured.”
MH002 is currently the most advanced rationally-designed consortium therapy in the UC field. It was developed through MRM Health’s proprietary CORAL® Technology and comprises six well-characterized commensal strains, selected and optimized to tackle key disease-driving mechanisms with enhanced potency, resiliency, and engraftment. Production is via MRM Health’s breakthrough scalable and standardized cGMP manufacturing platform, allowing the manufacturing of complete consortia as a single drug substance. The ability of CORAL® to enable scalable, cost-effective manufacturing of complete optimized consortia in a single process is expected to provide both key regulatory and patient compliance advantages.
In addition to the recently completed UC trial, MH002 is being tested in an ongoing multi-center, open label Phase 2 study enrolling patients with acute Pouchitis, a rare disease with high unmet medical need.
Sam Possemiers, Chief Executive Officer at MRM Health, said: “These early clinical data are very important for the Company, since they further validate our proprietary CORAL® technology which underlies our portfolio of live biotherapeutic products. The data enables us to take the next steps in our business strategy where we will be engaging with regulatory agencies in all territories and potential new partners as well as driving forward the rest of our development portfolio.”
-Ends-
About MRM Health
MRM Health is a clinical-stage biotech developing innovative therapeutics for inflammatory, CNS and metabolic diseases. The Company’s most advanced program MH002 is in preparation for pivotal clinical development in Ulcerative Colitis, upon obtaining positive clinical results in a phase 2a clinical trial, and is being evaluated in the orphan disease indication Pouchitis. MRM Health leverages its proprietary disruptive CORAL® technology platform to design microbiome-based biotherapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to optimize them for faster onset-of-action and increased potency and robustness. A significant differentiator is the ability to manufacture these consortia as single drug substance in a single standardized, scalable and highly cost-effective process. In addition to the program in Inflammatory Bowel Diseases, MRM Health has ongoing preclinical programs in Parkinson’s Disease and Spondyloarthritis, and partnered programs with IFF in Type 2 Diabetes and NAFLD.
For more information, please visit the website at www.mrmhealth.com.
About IBD and UC
Ulcerative colitis (UC) is a chronic, autoimmune, inflammatory bowel disease (IBD) characterized by mucosal inflammation of the colon resulting in debilitating diarrhea, abdominal pain, and rectal bleeding with significant impact on quality of life of patients and an increased risk of colorectal cancer development. Whereas many treatments exist and are in development for moderate-to-severe UC, only very limited options are available for mild-to-moderate disease. Current therapies have a merely symptomatic anti-inflammatory and/or an immunosuppressant effect and in many cases fail to induce enduring remission and/or cause potentially severe adverse events. These treatments also do not tackle what is considered as one of the core problems of UC, the overall poverty of microorganisms present in the gut of UC patients, also termed gut dysbiosis. MH002 is designed to enrich the gut microbiome of UC patients and thereby tackle what is considered a root cause of the disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919596456/en/
Contact information
For further information please contact:
M
RM Health
Dr Sam Possemiers – CEO
Christiane Verhaegen – CFO
Tel: +32.9.277.08.50
info@mrmhealth.com
Instinctif Partners (media)
Melanie Toyne-Sewell
Giulia Lasagni
Tel: +44 207 457 2020
MRMHealth@instinctif.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bsure Insights Now Available in the Microsoft Azure Marketplace5.12.2023 15:13:00 EET | Press release
Bsure today announced the availability of Bsure Insights in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. Bsure customers can now take advantage of the productive and trusted Azure cloud platform, with streamlined deployment and management. “Through our application, we give companies insights into their Microsoft users and licenses, giving them the tool they need to optimize their spend and reduce risk on their users, both member and guests,” said Henrik Skalmerud, CEO, Bsure. “We want to share our competency through the app, empowering companies to make informed decisions based on the information we give them, and this is available on the Azure Marketplace platform.” “Microsoft welcomes Bsure Insights to Azure Marketplace, where global customers can find, try, and buy from among thousands of partner solutions,” said Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp. “Azure Marketplace and trusted partne
Battery Manufacturer Hithium Joins Chile’s Clean Energy Association5.12.2023 15:00:00 EET | Press release
Stationary energy storage specialist Hithium has become a member of Chile’s renewable energy association ACERA. The manufacturer signed with the group at an event it hosted for partners and industry colleagues in Santiago, where Hithium representatives also introduced the company to the regional market and presented its latest product innovations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205316012/en/ Hithium joins ACERA in Chile (Photo: Business Wire) “We are committed to supporting the renewables industry in Chile, which is why it is important for us to join our clean energy sector colleagues here and become a member of ACERA,” said Mizhi Zhang, Hithium Head of Global Business, at the event. “As renewable energy generation grows, energy storage plays a key role in enabling the grid to incorporate clean power in a stable way. A big thanks to all our sector colleagues and partners who joined us tonight to celebrate
Moody’s Launches Moody’s Research Assistant, a GenAI Tool to Power Analytic Insights5.12.2023 15:00:00 EET | Press release
Moody's Corporation (NYSE:MCO) today announced the launch of Moody’s Research Assistant, a first-of-its-kind search and analytical tool powered by generative artificial intelligence (GenAI). Leveraging Moody’s extensive proprietary content and the latest large language models (LLMs), the product helps customers generate new insights from the breadth and depth of Moody’s credit research, data, and analytics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205410924/en/ As the first GenAI-powered research tool commercially available for financial market participants, Moody’s Research Assistant synthesizes vast amounts of information so users can assess lending or investment opportunities, monitor developments, compare entities, and enhance analytical workflows rapidly and at scale. Grounded in Moody’s extensive proprietary content in combination with the latest GenAI technology, Moody’s Research Assistant allows users to gen
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza5.12.2023 15:00:00 EET | Press release
Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this grant, Exscientia aims to harness the activation of the host interferon response as a therapeutic approach for pandemic influenza. The grant comes in the context of the wider Pandemic Antiviral Discovery (PAD) initiative. Out of the COVID-19 pandemic experience, jointly with the Novo Nordisk Foundation and the Bill & Melinda Gates Foundation, Open Philanthropy launched the PAD initiative to help catalyse the discovery and early development of novel antiviral medicines in preparation for future pandemics. “We are thrilled that these expert institutions are supporting Exscientia’s capabilities to develop innovative solutions to address significant unsolved health issues, expressed through this grant,” said Professor Ian Goodfellow, Vice President of Antivirals at Exscientia. “If we mana
Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion5.12.2023 15:00:00 EET | Press release
Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura ®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205198764/en/ This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom